Are blood-pressure targets needed to prevent cardiovascular disease?

Aletta E Schutte^{1

2

3}

Affiliations

¹ School of Population Health, University of New South Wales, Sydney, New South Wales, Australia. a.schutte@unsw.edu.au.
² The George Institute for Global Health, Sydney, New South Wales, Australia. a.schutte@unsw.edu.au.
³ Hypertension in Africa Research Team, Medical Research Council Unit for Hypertension and Cardiovascular Disease, North-West University, Potchefstroom, South Africa. a.schutte@unsw.edu.au.

Comment

Aletta E Schutte. Nat Rev Cardiol. 2021 Sep.

. 2021 Sep;18(9):615-616.

doi: 10.1038/s41569-021-00595-4.

Aletta E Schutte^{1

2

3}

¹ School of Population Health, University of New South Wales, Sydney, New South Wales, Australia. a.schutte@unsw.edu.au.
² The George Institute for Global Health, Sydney, New South Wales, Australia. a.schutte@unsw.edu.au.
³ Hypertension in Africa Research Team, Medical Research Council Unit for Hypertension and Cardiovascular Disease, North-West University, Potchefstroom, South Africa. a.schutte@unsw.edu.au.

No abstract available

Comment on

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
Blood Pressure Lowering Treatment Trialists' Collaboration. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2021 May 1;397(10285):1625-1636. doi: 10.1016/S0140-6736(21)00590-0. Lancet. 2021. PMID: 33933205 Free PMC article.
Final Report of a Trial of Intensive versus Standard Blood-Pressure Control.
SPRINT Research Group; Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, Cutler JA, Evans GW, Johnson KC, Kitzman DW, Oparil S, Rahman M, Reboussin DM, Rocco MV, Sink KM, Snyder JK, Whelton PK, Williamson JD, Wright JT Jr, Ambrosius WT. SPRINT Research Group, et al. N Engl J Med. 2021 May 20;384(20):1921-1930. doi: 10.1056/NEJMoa1901281. N Engl J Med. 2021. PMID: 34010531 Free PMC article. Clinical Trial.

1. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1223–1249 (2020). - DOI
1. The SPRINT Research Group. Final report of a trial of intensive versus standard blood-pressure control. N. Engl. J. Med. 384, 1921–1930 (2021). - DOI
1. The Blood Pressure Lowering Treatment Trialists’ Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet 397, 1625–1636 (2021). - DOI
1. Kallioinen, N., Hill, A., Horswill, M. S., Ward, H. E. & Watson, M. O. Sources of inaccuracy in the measurement of adult patients’ resting blood pressure in clinical settings: a systematic review. J. Hypertens. 35, 421–441 (2017). - DOI
1. Fatani, N., Dixon, D. L., Van Tassell, B. W., Fanikos, J. & Buckley, L. F. Systolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension. J. Am. Coll. Cardiol. 77, 1290–1299 (2021). - DOI